Dental and medical compositions having multiple sources of metal ions - Patents.com
Bioceramic compositions with multiparticulate crystalline double metal silicates enhance bioactivity and mechanical strength, addressing limitations of existing bioceramics by promoting tissue regeneration and repair through controlled ion release.
Patent Information
- Application Number
- JP2021514331
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-12
- Filing Date
- 2019-09-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-09-13
AI Technical Summary
Existing bioceramic compositions for dental and medical applications lack sufficient bioactivity, mechanical strength, and handling properties, limiting their effectiveness in restorative and sealing materials.
Development of bioceramic compositions comprising multiparticulate crystalline double metal silicates, such as strontium-akermanite, akermanite, bagdadite, and hardystonite, which release multiple metal ions like Ca²⁺, Mg²⁺, Zr⁴⁺, Sr²⁺, and Zn²⁺, promoting tissue regeneration and repair by forming a silica-rich layer and enhancing bioactivity.
The compositions exhibit improved bioactivity, mechanical strength, and handling properties, facilitating tissue regeneration and repair by stimulating cell differentiation and promoting the formation of a silica-rich layer, suitable for dental and medical applications.
Smart Images

Figure 0007590320000006 
Figure 0007590320000007 
Figure 0007590320000008
Abstract
Description
[Technical field]
[0001] The present invention is in the fields of medicine and dentistry. [Background technology]
[0002] Caries is a process caused by bacteria that leads to the destruction of dental tissues and, if not treated in a timely manner, can result in the loss of dental elements. Once it occurs, its progression can be divided into three stages. In the first stage, the caries only reaches the enamel of the tooth. In the second stage, the caries deepens and penetrates the dentin. In the third stage, the caries reaches the root canals. In the second stage, and mainly in the third stage, toothache is mainly caused by the inflammatory process caused by the bacterial invasion.
[0003] To prevent the caries process and restore normal tooth function, various techniques and procedures using various materials are used in the treatment of caries. After caries diagnosis, the first step is the total or partial removal of the carious tissue, followed by the steps of protection of the dental pulp (arteries, veins and nerves) and definitive restoration of the tooth. Two materials are used in tooth restoration. The first material, called intermediate restorative, is used internally and has biological properties that protect the dental pulp, while the second material, called definitive restorative, is used externally and restores the external shape of the tooth. The protection of the dental pulp with intermediate restorative materials before the final restorative materials is required because the final restorative materials do not have biological properties that protect the dental pulp and are usually invasive to the dental pulp. It is desirable that these intermediate materials have the bioactive ability to promote the repair of the dental pulp and the remaining dentin, as well as the ability to create a harsh environment for bacterial growth due to their high pH.
[0004] Among the products commonly used as final restorative or root canal filling materials are calcium hydroxide and glass ionomer cements, but in recent years, with the development of bioactivity evaluation methods, it is known that the effectiveness of these materials in treatments is influenced by their properties. Some studies have demonstrated that for indirect pulp capping procedures in primary or permanent teeth (Marchi JJ, de Araujo FB, Froner AM, Straffon LH, Nor JE (2006) "Indirect pulp capping in the primary dentition: a 4-year follow-up study" Journal of Clinical and Pediatric Dentistry 31, 68-71; Baratieri LN, Machado A, Van Noort R, Ritter AV, Baratieri NMM (2002) "Effect of pulp protection technique on the clinical performance of amalgam restorations: three-year results" Operative Dentistry 27, 319-24), for example, the bioactive effect of calcium hydroxide or glass ionomer-based cements in carious lesions is very low and equivalent to inert materials such as wax (Corralo DJ, Maltz M (2013) "Clinical and ultrastructural effects of different liners / restorative materials on deep carious lesions" Journal of Clinical and Pediatric Dentistry 31, 68-71; Baratieri LN, Machado A, Van Noort R, Ritter AV, Baratieri NMM (2002) "Effect of pulp protection technique on the clinical performance of amalgam restorations: three-year results" Operative Dentistry 27, 319-24). dentin: A randomized clinical trial.” Caries Research 47, 243–50).
[0005] Bioceramics can be classified as bioinert, bioactive or bioresorbable based on their surface chemical reactivity (Heness G, Ben-Nissan B (2004). Innovative bioceramics. Materials Forum, 27, 104-14;10). Bioactive materials are materials that can form chemical bonds with living tissue. In the context of bone replacement materials, the bioactivity of a material is commonly characterized by its ability to induce the formation of an apatite layer on its surface after immersion in biological fluids (Hench LL, Splinter RJ, Allen W, Greenlee T (2004) "Bonding mechanisms at the interface of ceramic prosthetic materials." Journal of Biomedical Materials Research, 5, 117-141).
[0006] After the preliminary definition of biomaterials (first generation of implantable materials) in the 1950s, based mainly on the criteria of maximum biochemical and biological inertia when in contact with body fluids, the discovery of bioactive glasses by Larry L. Hench in 1969 was the first inorganic material exhibiting bioactivity, and thus an alternative to the materials used for implants at that time.
[0007] One of the main bioactive features of these bioactive glasses was based on the activity of Ca and Si ions present in their composition, which are able to induce the formation of a carbonate hydroxyapatite layer on their surface similar to the mineral phase of bone (Baino F, Hamzehlou S, Kargozar S (2018) "Bioactive Glasses: Where Are We and Where Are We Going?" Journal of Functional Biomaterials 9, 25).
[0008] The second generation of bioactive glasses extends the concept of biocompatibility by forming strong and stable tissue-implant bonds with the tissues in which they are placed, thus promoting favorable responses in biological systems (Fiume E, Barberi J, Verne E, Baino F (2018) "Bioactive Glasses: From Parent 45S5 Composition to Scaffold-Assisted Tissue-Healing Therapies." Journal of Functional Biomaterials 9, 24).
[0009] In the 80s, it was discovered that bioactive glasses, when used in particulate form, can promote regeneration and stimulate osteogenic development, a bone formation process. Later, it was discovered that metal ions present in the composition and released during the dissolution of bioactive glasses are responsible for stimulating growth factors and cell differentiation (Hench LL and Jones JR (2015) "Bioactive Glasses: Frontiers and Challenges." Frontiers in Bioengineering and Biotechnology 3, 194).
[0010] Despite their high bioactivity, bioactive glasses have an amorphous non-crystalline structure with numerous physical and chemical disadvantages, including high brittleness, low bending strength, low adhesion, difficult handling, low adhesion and high solubility. One of the methods found for the use of bioactive glasses is in the form of scaffolds, which limits their clinical application (Wu C and Chang J (2013) "A review of bioactive silicate ceramics." Biomedical Materials 8, 032001).
[0011] In the late 60s, interest arose in the use of various ceramic materials in biomedical applications as alternatives to bioactive glasses, mainly because ceramic materials exhibit low solubility and good mechanical strength. After a while, these materials were designated bioceramics (Dorozhkin SV (2010) "Calcium Orthophosphates as Bioceramics: State of the Art." Journal of Functional Biomaterials, 1, 22-107).
[0012] Over the past few years, new dental compositions based on these new bioceramics have been proposed to replace calcium hydroxide and glass ionomer cements, with the main aim of increasing their bioactivity. Among these new bioceramics, there is a class of calcium silicate-based cements, which are ceramics presented as an alternative source of calcium, available in powder / liquid form or in the form of a non-aqueous paste.
[0013] Studies have shown a link between the ion release rate and the bioactivity of bioceramics. Calcium-rich compositions have shown a correlation with the Ca 2+ Although calcium may seem more attractive because it releases calcium ions faster and promotes the formation of an apatite hydroxide layer on its surface, calcium does not seem to be an essential element in the composition for ceramics to be bioactive. This fact is evidenced by nanostructured forsterite, which is degradable and bioactive even though it is a calcium-free material (Kharaziha M, Fathi MH (2009) "Synthesis and characterization of bioactive forsterite nanopowder." Ceramics International, 35, 2449-2454). Thus, calcium silicate-based bioceramic compositions have the ability to release calcium ions, but also other metal ions (Mg, Mg, Mg) that are essential for higher bioactivity and can induce complete regeneration and repair. 2+ , Zr 4+ , Sr2+ , Zn 2+ ) in the bone. It has been proven that metal ions play a key role in a myriad of processes related to cell repair and regeneration in addition to stimulating bone formation (Mohammadi H, Hafezi M, Nezafati N, Heasarki S, Nadernezhad A, Ghazanfari SMH, Sepantafar M (2014) "Bioinorganics in Bioactive Calcium Silicate Ceramics for Bone Tissue Repair: Bioactivity and Biological Properties." Journal Ceramic and Science Technology 5, 1-12). This bioactive process is directly correlated with the metal ion exchange rate at the ceramic interface along with the physiological environment surrounding the ceramic, thus inducing the formation of a silica-rich layer at the ceramic surface (Iwata NY, Lee GH, Tokuoka Y, Kawashima N (2004) "Sintering behavior and apatite formation of diopside prepared by coprecipitation process." Colloids and Surfaces B, 34, 239-245).
[0014] In dentistry, regeneration is defined as the formation of physiological dentin, whereas repair is the formation of new tissue with the expected physiological functions, similar to the natural pulp-dentin complex at the histological level (Smith AJ, Duncan HF, Diogenes A, Simon S, Cooper PR (2016) "Exploiting the bioactive properties of the dentin-pulp complex in regenerative endodontics." Journal of Endodontics 42, 47-56). One of the main goals of dental procedures is the complete regeneration of tissues lost due to injury, but it is unlikely that currently commercially available bioceramic compositions can significantly stimulate tissue regeneration and repair.
[0015] In the study, calcium (Ca 2+ ), silicon (Si 4+ ), Strontium (Sr 2+ ), Zinc (Zn 2+ ), Boron (B 3+ ), Vanadium (V 3+ ), Cobalt (Co 2+ ), Magnesium (Mg 2+ ) and zirconium (Zr 4+ It has been shown that metal ions such as arginine, arginine, and arginine play a physiological role in angiogenesis, which is involved in bone metabolism and is involved in the growth and mineralization of bone tissue. Metal ions act as enzyme cofactors and thus affect cell signaling pathways, stimulating the actions that occur during tissue formation. These actions make metal ions attractive for use as therapeutic agents in the field of hard and soft tissue engineering by promoting regeneration and repair (Hoppe A, Guldal NS, Boccaccini AR (2011), "A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics." Biomaterials 32, 2757-2774).
[0016] Bioceramic cements with bioactive properties, i.e. the ability to release metal ions, were first reported by Torabinejad in US Patent No. 5,415,547, where a Portland cement-based restorative for dental structures known as mineral trioxide aggregate (MTA) was proposed. The product uses calcium silicate, which is less soluble than calcium hydroxide, as a calcium ion source, but has poor physicochemical properties, since the product is essentially Portland cement in powder form added with a radiopaque agent. Although they are considered materials with a certain degree of bioactivity, and their decomposition products do not induce inflammatory reactions, calcium silicate-based cements show a number of drawbacks related to their physical and biological properties, including low mechanical strength that makes them unsuitable for load-bearing applications, and low chemical stability (high decomposition rate) that leads to highly alkaline conditions in the surrounding environment that are detrimental to cell viability and limit their biological applications in the long term. In the literature, numerous reports can be found about the difficulties of using MTA, mainly due to its poor handling properties.
[0017] In US Patent Application No. 2003 / 0159618, Primus disclosed a method for producing white dental cement without the presence of iron and based on the composition of Portland cement. This method results in a material that can be used as a restorative dental cement. However, this method only reduced the iron content and did not improve the physical and biological properties of these materials.
[0018] In U.S. Pat. No. 8,475,811, Yang developed a hydraulic cement formulation for dental and orthopedic applications. In U.S. Pat. No. 8,475,811, the focus was placed on obtaining a premixed paste with the ability to harden in the humidity of a physiological medium due to the presence of calcium silicate and anhydrous carrier liquid. In the formulation developed by Yang, the hardening mechanism occurs through the hydration of tricalcium silicate (Ca3SiO5) and dicalcium silicate (Ca2SiO4) phases, which, upon contact with the humidity of a physiological environment, hydrate to form two new phases: a calcium hydroxide phase (Ca(OH)2) and a silicic acid hydrate gel phase (3CaO2SiO2.3H2O), known as CSH. The entanglement of this CHS phase with calcium hydroxide plates due to medium saturation reduces the fluidity of the particles and promotes the hardening of the material. The hydration reaction of tricalcium silicate (Ca3SiO5) and dicalcium silicate is represented by the following equation: 2Ca3SiO5+6H2O→3CaO.2SiO2.3H2O+3Ca(OH)2 2Ca2SiO4+4H2O→3CaO.SiO2.3H2O+Ca(OH)2 This is carried out in accordance with:
[0019] Although a single injectable calcium silicate paste solved the problem of handling MTA (powder / liquid), Yang's ready-to-use cement did not provide additional metal ions to improve MTA bioactivity, and both formulations had calcium silicate as the only calcium ion source.
[0020] In US Patent No. 8,765,163 B2, Zreiqat discloses a new biocompatible material, which is described as zinc and calcium silicate. The material was developed for use in regenerative tissues, including bone tissue. The proposed material was also described for use as a coating to improve the long-term stability of implantable medical devices. The material described by Zreiqat refers to hardystonite (Ca2ZnSi2O7) modified with Sr, Mg or Ba by sol-gel synthesis. After modification, hardystonite contains strontium, zinc and has the following formula Sr 0.1 Ca 1.2 The sintered parts or implants are converted into new calcium silicate structures with ZnSi2O7. Zreigat's disclosure specifically relates to materials used as implants for 3D, orthopedic, dental, spinal, craniofacial reconstruction, alveolar augmentation and cartilage regeneration prostheses, among other types of implants. Although the implantable medical devices show good bioactivity due to the presence of other metal ions in addition to calcium, this was only provided in the form of devices that precludes their use as restorative and / or sealing materials. Therefore, these sintered parts or implants cannot be used in certain situations, such as the induction of apical formation in vital permanent teeth with inflamed pulp (apexogenesis) or the formation of an apical barrier of hard tissue in young teeth with incompletely formed roots and necrotic pulp (apexification).
[0021] Therefore, there is a need for the development of medical and dental compositions with the desired bioactivity that allows their use as restorative and / or root sealant materials with an increased biological response, in addition to suitable physicochemical properties for handling and setting time (Da Rosa WLO, Cocco AR, Silva TM et al. (2018) "Current trends and future perspectives of dental pulp capping materials: a systematic review." Journal of Biomedical Materials Research. Part B, Applied biomaterials 106, 1358-1368). Currently, it takes considerable efforts in the medical and dental fields to obtain and develop materials with good bioactive properties, since existing bioceramic compositions have not been developed with their biological potential in mind (Sadaghiani L, Gleeson HB, Youde S, Waddington RJ, Lynch CD, Sloan AJ (2016) "Growth factor liberation and DPSC response following dentine conditioning." Journal of Dental Research 95, 1298-1307).
[0022] The use of silicates of multiple metal ions in the manufacture of medical and dental implants is known in the art. Several references report positive effects of the use of bone or dental implants containing such silicates on the physiological and restorative aspects of sintered forms of parts or implants made with silicates.
[0023] However, these sintered parts or implants cannot be used in certain situations, especially where a flow of material is required for complete filling of the affected medical or dental application site, such as in endodontic filling or resorption of the root of a tooth or the opposing surface of a fractured bone, or filling of a gap between bone or teeth with an implant. Summary of the Invention [Problem to be solved by the invention]
[0024] The present disclosure improves bioactivity compared to bioceramics described in the prior art by solving the structural problems of bioactive glasses of amorphous composition and providing a significant difference from the prior art in bioceramic compositions that increase bioactivity in situations that depend on material flow for complete filling. [Means for solving the problem]
[0025] The present disclosure provides bioceramic compositions for medical and dental use comprising a multiparticulate crystalline double metal silicate. In some embodiments, the multiparticulate crystalline double metal silicate is a sorosilicate. In some embodiments, the sorosilicate is strontium-akermanite (Sr2MgSi2O7), akermanite (Ca2MgSi2O7), bagdadite (Ca3ZrSi2O9), hardystonite (Ca2ZnSi2O7), or combinations thereof. [Brief description of the drawings]
[0026] [Figure 1] FIG. 1 is a graph showing the X-ray diffraction pattern of pure akermanite obtained by solid state reaction. [Diagram 2] 1 is a graph showing the granulometry distribution of baghaddite particles. [Figure 3A] Figure 3 shows a set time assay: Figure 3A shows a Gilmore type metal indenter and a stainless steel ring die. [Figure 3B] Figure 3B shows a set time assay. Figure 3B shows vertical indentation of a sample onto a horizontal surface. [Figure 3C] Figure 3C shows the set time assay, Figure 3D shows the indentation marks until they were no longer visible. [Figure 4A]Figure 4 shows solubility testing: Figure 4A shows a stainless steel ring mold filled with samples. [Figure 4B] Figure 4B shows a petri dish containing hardened samples after being covered with water for 24 hours. [Figure 4C] Figure 4C shows the sample after drying. [Figure 5A] 5A shows a glass plate with a sample, and FIG. [Figure 5B] Figure 5B shows a flow test, Figure 5B shows two glass plates and an additional mass. [Figure 5C] Figure 5C shows a compressed sample disk. [Figure 6A] 6A-6C show radiopacity testing: Figure 6A shows the polypropylene ring mold and aluminum step wedge filled with the sample. [Figure 6B] 6A-6C show radiopacity testing.FIG 6B shows polypropylene ring mold and aluminum step wedge filled with sample. [Figure 6C] 6A-6C show radiopacity testing, and FIG 6C shows polypropylene ring molds and aluminum step wedges filled with samples. [Figure 7A] 7A-7D show a test for determining film thickness of a composition of the present disclosure.FIG 7A shows two optically flat squares and a loading device. [Figure 7B] 7A and 7B show a test for determining film thickness of a composition of the present disclosure, and FIG. [Figure 7C] 7A-7C show a test for determining film thickness of compositions of the present disclosure. [Figure 8]Graph showing cell viability determined using the MTT assay. Asterisks indicate significant differences compared to the control group (*p<0.05; **p<0.01, p<0.001), where CB5 is a bioceramic composition sealer, CS1 is a commercial bioceramic sealer, CB6 is a bioceramic composition restorative, CR1 is a commercial bioceramic restorative, CS2 is a commercial bioceramic sealer, CR2 is a commercial bioceramic restorative, and CC1 is a commercial resin sealer. The order of the bars in each set from left to right is control, CB5, CS1, CB6, CR1, CS2, CR2, and CC1. [Figure 9] 1 is a graph showing human stem cell (hDPSC dental pulp) migration exposed to various cement extracts and assessed by an in vitro scratch wound healing assay, where CB5 is a bioceramic composition sealer, CS1 is a commercial bioceramic sealer, CS2 is a commercial bioceramic sealer, and CC1 is a commercial resin sealer. [Figure 10] FIG. 1 is a graph showing human stem cell (hDPSC dental pulp) migration exposed to various cement extracts and assessed by an in vitro scratch wound healing assay, where CB6 is a bioceramic composite restorative, CR2 is a commercial bioceramic restorative, and CC1 is a commercial resin sealer. [Figure 11] FIG. 1 shows cell adhesion of human stem cells (hDPSC dental pulp) exposed to an extract of a bioceramic composition sealer (CB5) and then assessed by an in vitro scratch wound healing assay. [Figure 12] FIG. 1 shows cell adhesion of human stem cells (hDPSC dental pulp) exposed to extracts of bioceramic composition restorative material (CB6) and then assessed by an in vitro scratch wound healing assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] The inventors have verified that multiparticulate crystalline double metal silicates can be incorporated into dental or bone cement formulations, and that the dissolution rate and pH around the application area are physiologically acceptable. The inventors have also verified that certain silicates, when in multiparticulate form, have structuring properties in the cavity or application area.
[0028] The present disclosure provides a method for the preparation of a Ca 2+ , Mg 2+ , Zr 4+ , Sr 2+ , Zn 2+ The present invention provides a bioceramic composition in powder / liquid or paste form, comprising a multiparticulate crystalline double metal silicate as a metal ion source, such as . The disclosed composition can be used in medical and dental applications, for example, for use in tissue regeneration, including bone tissue. However, it is recognized that the composition is not limited to these particular applications.
[0029] Crystalline double metal silicates are anionic groups (SiO) with oxygen ions attached and thus six negative charges (-6). 6- Sorosilicate is a silicate material with a crystal structure of two tetrahedra of 2 / 7 silicon / oxygen ratio, which has an hourglass shape, a central oxygen ion is shared by the double tetrahedrons with a silicon / oxygen ratio of 2 / 7, and the double tetrahedrons are bonded together by the various metal cations present in the composition. Compounds with said structure are named sorosilicates.
[0030] The structure of sorosilicates shows differences in crystal structure and chemical composition when compared to nesosilicates such as tricalcium silicate (Ca3SiO5) and dicalcium silicate (Ca2SiO4). Nesosilicates are made up of separated silica tetrahedra (SiO4) 4- It has a crystal structure of a single metal ion, Ca 2+ The crystal structure of sorosilicates consists of two silica tetrahedra (SiO) connected by a shared oxygen atom via a covalent bond (Si-O). 6- These double silica tetrahedra are composed of Ca2+ , Mg 2+ , Zr 4+ , Zn 2+ and Sr 2+ is bound by two metal ions selected from
[0031] Due to their crystal structure and chemical composition, sorosilicates have unique properties in terms of bioactivity: their two silica tetrahedra confer low solubility to sorosilicates, and the release of their multiple metal ions in a constant and balanced manner can promote osteogenic differentiation of osteoblasts, dental pulp cells, bone marrow stromal cells, adipose tissue-derived stem cells, fibroblasts and periodontal ligament cells (Hoppe A, Guldal NS, Boccaccini AR (2011), "A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics." Biomaterials 32, 2757-2774) and in vivo bone regeneration.
[0032] Furthermore, sorosilicates have a relatively wide range of chemical compositions and their physical, chemical and biological properties can be optimized to meet tissue regeneration requirements according to the type of metal ion used.
[0033] Examples of suitable crystalline double metal silicates include compounds from the sorosilicate group, such as strontium akermanite (Sr2MgSi2O7), akermanite (Ca2MgSi2O7), bagdadite (Ca3ZrSi2O9) and hardystonite (Ca2ZnSi2O7).
[0034] The structuring mechanism of the bioceramic compositions described herein is different from calcium silicate-based compositions, which form CSH phases upon hydration. When the bioceramic compositions described herein come into contact with water, the calcium sulfate hemihydrate (CaSO4.1 / 2H2O) present in the bioceramic compositions dissolves to dihydrate (CaSO4.2H2O), which is less soluble and saturates in physiological environments, eventually precipitating into needle-like crystals. The imbrication of these needle-like calcium sulfate dihydrate (CaSO4.2H2O) with hydrous sorosilicate crystals (M1.M2.SiO7.H2O) provides the bioceramic compositions described herein with cohesion and mechanical strength, while at the same time, the interaction between the growing crystals results in small desirable expansions, and the reaction mechanism is as follows: M1M2Si2O7+(CaSO4.1 / 2H2O)+H2O→M1.M2.Si2O7.H2O+CaSO4.2H2O +Heating (wherein M1 and M2 are Ca 2+ , Mg 2+ , Zr 4+ , Sr 2+ and Zn 2+ are independently selected from It can be shown as:
[0035] The bioceramic compositions disclosed herein, upon contact with bodily fluids, react with metal ions (M + =Ca 2+ , Mg 2+ , Zr 4+ , Sr 2+ or Zn 2+ ), which is silicon-oxygen-metal (Si-OM) + ) bond is broken to produce H + Then, these H + The ion is silicate (Si2O7) 6- to form a silica-rich amorphous colloidal layer known as silanol (Si—OH), the reaction being represented by the following formula: Si-OM + +H + +OH - →Si-OH+M +(aqueous solution)+OH - As shown in the figure.
[0036] After the formation of silanol groups, the pH of the solution increases at the surface of the material, causing its condensation and repolymerization to form the following formula: Si-OH+Si-OH→Si-O-Si+H2O A silica gel layer is formed on the surface of the bioceramic composition according to the reaction shown in FIG.
[0037] As a result of these initial steps, the surface of the bioceramic composition disclosed herein exhibits an alkaline pH and sufficient concentration of multiple metal ions, and this constant release of metal ions in a chemically balanced environment allows for enzymatic changes that influence and stimulate cell differentiation and thus tissue formation, promoting the repair and regeneration of the affected area, more specifically the tissue-bone and dentin-pulp complexes.
[0038] In one embodiment, the bioceramic composition is available in the form of a powder phase and an aqueous liquid carrier.
[0039] In one embodiment, the bioceramic composition is available in the form of a non-aqueous paste.
[0040] In a further aspect, the bioceramic composition exhibits radiopacity, i.e., the ability of the material to reflect X-rays used in radiological examinations. This characteristic is very important for materials used within the dental and medical fields. To impart this characteristic to the material, various radiopaque agents can be used in both powder and paste form, such as, but not limited to, derivatives of barium, zirconium, bismuth, tantalum, titanium, tungsten, among others. Examples of suitable radiopaque agents include barium sulfate, zirconium oxide, bismuth oxide, tantalum oxide, titanium oxide, and calcium tungstate. In one embodiment, the radiopaque agent is calcium tungstate.
[0041] In a further aspect, the bioceramic composition includes a hardening agent. To impart this hardening to the composition, various hardening agents, such as calcium acetate, calcium sulfate, calcium carbonate, calcium oxalate, potassium sulfate, or combinations thereof, can be used in both powder and paste forms. In one embodiment, the preferred hardening agents are calcium sulfate and potassium sulfate.
[0042] In some embodiments, water is used as a carrier for the liquid phase of the composition.
[0043] In a further embodiment, the bioceramic composition includes an accelerator. To impart this characteristic to the material, various accelerators can be used in the aqueous liquid carrier, including at least one selected from calcium chloride, calcium nitrate, calcium formate, calcium gluconate, calcium lactate, citric acid, or combinations thereof.
[0044] For example, a suitable plasticizer of the composition may be used in the liquid phase, such as at least one of materials derived from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, or combinations thereof.
[0045] A suitable non-aqueous liquid carrier for a composition in the form of a non-aqueous paste may be a member of the glycol family, such as ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, diethylene glycol dimethyl ether, diethylene glycol monoethyl ether, butylene glycol, or combinations thereof.
[0046] The bioceramic compositions disclosed herein may also include a rheology control agent incorporated into the paste for rheology adjustment. Suitable rheology control agents may be selected from the various silicon oxide groups of micro- and nano-sized inorganic particles, such as hydrophilic pyrogenic silica, silicon oxide, fumed silica, or combinations thereof.
[0047] In one embodiment, the bioceramic composition has a powder phase and an aqueous liquid carrier, the solid phase comprises 20-90% by weight of at least one multiparticulate crystalline double metal silicate, 10-50% by weight of a radiopaque agent, 1-20% by weight of a hardener, and the aqueous liquid carrier comprises 50-98% by weight of a vehicle, 2-30% by weight of an accelerator, and 0.5-10% by weight of a plasticizer. In one embodiment, the solid phase comprises 40-70% by weight of at least one multiparticulate crystalline double metal silicate, 20-40% by weight of a radiopaque agent, 2-10% by weight of a hardener, and the aqueous liquid carrier comprises 70-85% by weight of a vehicle, 5-20% by weight of an accelerator, and 1-5% by weight of a plasticizer.
[0048] In one embodiment, the bioceramic composition in non-aqueous paste form comprises 10-60 wt% of at least one multiparticulate crystalline double metal silicate, 30-70 wt% of a radiopaque agent, 1-20 wt% of a hardening agent, 0.5-10 wt% of a rheology control agent, and 20-60 wt% of a non-aqueous liquid carrier. In one embodiment, the bioceramic composition comprises 20-40 wt% of at least one multiparticulate crystalline double metal silicate, 20-40 wt% of a radiopaque agent, 2-10 wt% of a hardening agent, 1-5 wt% of a rheology control agent, and 20-40 wt% of a non-aqueous liquid carrier.
[0049] In a further embodiment, the present invention provides a method of inducing tissue regeneration comprising placing a bioceramic composition of the present invention into the tissue to be repaired.
[0050] The present disclosure also includes the use of the disclosed bioceramic compositions for dental and medical applications, for example, for use in tissue regeneration, including bone tissue.
[0051] Particular illustrations of the invention are given in the following examples, which, however, are illustrative of preferred embodiments of the invention and therefore should not be construed as limiting its scope. EXAMPLES
[0052] Example 1 Preparation of bioceramic compositions in powder / liquid form For Bioceramic Compositions 1 and 2 listed in Table 1, the solid components were first prepared in powder form using a planetary mixer at a speed of less than 400 rpm for about 30 minutes until completely homogenized in the following order: sorosilicate, radiopaque agent, and hardener. An aqueous liquid carrier was prepared using a mechanical stirrer, and the components were added in the following order: water, accelerator, and plasticizer at a speed of less than 800 rpm for about 60 minutes until completely homogenized.
[0053] [Table 1]
[0054] Example 2 Preparation of a bioceramic composition in non-aqueous paste form The bioceramic compositions in Table 2 below were prepared by mixing the liquid components (carrier) and solid components in the following order: sorosilicate, radiopaque agent, rheology control agent, and curing agent with a mechanical stirrer at a speed of less than 500 rpm for approximately 45 minutes until completely homogenized.
[0055] [Table 2]
[0056] Example 3 Physicochemical characterization of bioceramic compositions The sorosilicate component was characterized by X-ray diffraction to identify the component phases and by laser diffraction to identify its particle size distribution. Figure 1 shows the X-ray diffraction pattern, showing the identification of the characteristic peaks of akermanite sorosilicate due to the presence of the Ca2MgSi2O7 crystalline phase. Figure 2 shows the particle size distribution of the akermanite phase, which has a d50 of less than 1.58 μm.
[0057] The physicochemical characterization of bioceramic compositions 1-6 was carried out according to ISO6876:2012-Dental root canal sealants. For the determination of the setting time, three specimens of each composition described in examples 1 and 2 were produced and kept in a climate chamber at 37±1°C and 95±5%. 10 minutes after sample preparation, they were marked with a Gillmore needle. The time elapsed from the start of sample production to the point when any type of needle mark could no longer be visualized on the surface of the material was recorded (Figure 3A-C). The setting time results are shown in Table 3.
[0058] For the solubility test, two coupons were prepared containing each composition described in Examples 01 and 02, with a diameter of 20 mm and a height of 1.5 mm. The samples were kept in a Petri dish in distilled water at 37° C. for 24 hours. After this period, the water with the sample was filtered through filter paper and collected in a second Petri dish (initial mass). This plate was kept in a heated muffle furnace at 100° C. to completely evaporate the water. The solubility was determined by the difference between the initial and final mass of the Petri dish (FIGS. 4A-C). The results are shown in Table 3.
[0059] Flow was determined using three samples of each bioceramic composition 1-4 described in Examples 1 and 2. Two glass plates with dimensions of 40 mm (height) x 40 mm (width) x 5 mm (thickness) were used. Using a graduated syringe, 0.050 ± 0.005 ml of each sample was placed on one of the glass plates. 180 seconds after the start of sample preparation, the other glass plate and a 100 g weight were placed on the material. 10 minutes after the start of the test, the weight was removed and the maximum and minimum diameters of the disks formed by the bioceramic compositions were measured (Figures 5A-C). The flow results are shown in Table 3.
[0060] To determine the radiopacity of bioceramic compositions 1-6 of Examples 1 and 2, coupons with a diameter of 10 mm and a height of 1.00 ± 0.01 mm were generated. For optical density comparison, the samples were placed in close proximity to an aluminum scale (1-7 mm Al). Images were captured using a digital sensor along with an X-ray emitter (Figures 6A-C). Radiopacity results are shown in Table 3.
[0061] The film thickness of bioceramic compositions 1-4 of Examples 1 and 2 was determined by applying the material between two flat square glass plates with a thickness of 5 mm and a contact surface of approximately 200 mm2. Three minutes after application of the material, a load of 150 N was applied to the set and the film thickness was measured with a micrometer (Figures 7A-C). This assay was repeated three times for each composition. The film thickness results are shown in Table 3.
[0062] [Table 3]
[0063] Ion release from bioceramic compositions 1-6 was determined by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Samples were prepared according to the procedures described in Examples 1 and 2. Disks of the prepared samples were kept in 30 mL of simulated body fluid (SBF) solution at pH 7.25 at 37°C and evaluated on days 1, 3, 5, 7, 10 and 20. The concentrations of ions from SBF were similar to those found in human plasma by Kokubo (Kokubo T (1990) "Surface chemistry of bioactive glass-ceramics" Journal of Non-Crystalline Solids 120, 138-151). Aliquots of the solution were withdrawn on days 1, 3, 5, 10 and 20 to determine the ions in solution (Ca 2+ , Mg 2+ , Zr 4+ , Zn 2+ , Si 4+ The concentrations of ) were determined by ICP-AES as shown in Table 4. The pH variation of the resulting solutions was also determined by a digital pH meter. The results are shown in Table 4.
[0064] [Table 4]
[0065] Example 4 Assay for determining hydroxyapatite formation To evaluate the ability of the bioceramic composition to form hydroxyapatite, samples with an average particle size of 1.5 μm were stored at 37° C. in a simulated body fluid (SBF) solution pH 7.25 and evaluated at 1, 3, 5, 7, 10 and 20 days using a mass / volume ratio of 1.5 mg / mL. After 20 days, the disks were washed with water and dried at 60° C. The amount of hydroxyapatite was determined by the phosphorus (P) content in the samples using energy dispersive X-ray fluorescence spectroscopy. The mass percentage measurements are related to hydroxyapatite formation. The results are shown in Table 5.
[0066] [Table 5]
[0067] While several embodiments have been shown and described herein, those skilled in the art will recognize that modifications and variations are possible in light of the above teachings.
[0068] Example 6 Cell viability in human stem cell (hDPSC dental pulp) A 72-hour colorimetric indicator 3-(4,5-dimethyl-thiazole)-2,5-diphenyl-tetrazolium bromide (MTT) assay was used to determine the viable cell number or cell viability after exposure to the bioceramic compositions.
[0069] When the cell viability observed after incubation was compared with the control (no cement) and the commercial resin sealer (CC1), the control showed the highest cell viability, while CC1 showed the lowest cell viability, i.e., poor results were shown for CC1.
[0070] Differences were also confirmed among the bioceramic composition sealer (CB5), the commercial bioceramic sealer (CS1), the bioceramic composition restorative material (CB6), the commercial bioceramic restorative material (CR1), the commercial bioceramic sealer (CS2) and the commercial bioceramic restorative material (CR2). The results are shown in Figure 8.
[0071] Example 7 Cell migration in human stem cells (hDPSC dental pulp) A gradual decrease in cell migration over time indicates a favorable response in terms of faster healing of the damaged area and healing rate.Migration of human stem cells (hDPSC dental pulp) in the presence of the bioceramic compositions, as well as in the presence of control and commercial resin sealers, was evaluated by an in vitro scratch wound healing assay.
[0072] Differences were also identified between the bioceramic composition sealer (CB5), the commercial bioceramic sealer (CS1), the bioceramic composition restorative (CB6), the commercial bioceramic restorative (CR1), the commercial bioceramic sealer (CS2) and the commercial bioceramic restorative (CR2), where the bioceramic composition sealer (CB5) and the bioceramic composition restorative (CB6) showed reduced cell migration when compared to the commercial bioceramic sealer (CS1) and restorative (CR2). The results are shown in Figures 9 and 10.
[0073] Example 8 Cell adhesion in human stem cells (hDPSC dental pulp) Cell adhesion was also assessed by an in vitro scratch wound healing assay. HDPSC cells were analyzed by differential staining with phalloidin (cell nuclei) and DAPI to visualize the actin cytoskeleton.
[0074] Cell adhesion results showed excellent interaction and adhesion between adjacent cells in the presence of the bioceramic composition. The bioceramic composition sealer (CB5) and bioceramic composition restorative (CB6) showed a progressive increase in growth over time, an expanded morphology and a high content of F-actin (cellular microfilaments), reaching confluence after 72 hours of culture.
[0075] The analyses of cell proliferation (by cell viability test), apoptosis, cell adhesion, as well as morphology (by cell adhesion test) and migration (by cell migration test) showed very favorable results, indicating that the proposed bioceramic composition induces odontoblastic / osteogenic mineralization and differentiation processes in the presence of tooth-specific human stem cells (hDPSC dental pulp). A commercial resin sealer was also used in the comparative tests, but all results were unfavorable for this product.
Claims
1. A bioceramic composition for medical or dental use comprising at least one sorosilicate, at least one liquid carrier and calcium sulfate as a hardening agent.
2. The sorosilicate is strontium akermanite (Sr 2 MgSi 2 O 7 ), Akermanite (Ca 2 MgSi 2 O 7 ), Baghdadites (Ca 3 ZrSi 2 O 9 ), Hardystonite (Ca 2 ZnSi 2 O 7 10. The bioceramic composition of claim 1, wherein the bioceramic composition is selected from the group consisting of: 100% sulphuric acid, ...
3. The bioceramic composition of claim 1 in the form of a powder phase and an aqueous liquid carrier.
4. The bioceramic composition of claim 1 in the form of a non-aqueous paste.
5. 10. The bioceramic composition of claim 1 comprising at least 10% by weight of sorosilicate.
6. 10. The bioceramic composition of claim 1 having a particle size distribution with a d50 of less than 150 microns.
7. 10. The bioceramic composition of claim 1 having a particle size distribution essentially with a d50 of less than 5 microns.
8. (a) the powder phase of the composition comprises: Optionally, at least one additional hardening agent selected from the group of calcium acetate, calcium carbonate, calcium oxalate, potassium sulfate, and combinations thereof; at least one radiopaque agent selected from the group consisting of barium sulfate, zirconium oxide, bismuth oxide, tantalum oxide, titanium oxide, and calcium tungstate, and combinations thereof; Including, (b) the aqueous liquid carrier of the composition is Water, at least one accelerator from the group consisting of calcium chloride, calcium nitrate, calcium gluconate, calcium lactate, calcium formate, citric acid, potassium sulfate, and combinations thereof; at least one plasticizer selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, and combinations thereof; The bioceramic composition of claim 3 comprising:
9. The non-aqueous paste form is at least one non-aqueous liquid carrier selected from the group consisting of ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, diethylene glycol dimethyl ether, diethylene glycol monoethyl ether, butylene glycol, and combinations thereof; at least one radiopaque agent selected from the group consisting of barium sulfate, zirconium oxide, bismuth oxide, tantalum oxide, titanium oxide, and calcium tungstate, and combinations thereof; Optionally, at least one hardening agent selected from the group consisting of calcium acetate, calcium carbonate, calcium oxalate, potassium sulfate, and combinations thereof; a rheology control agent comprising at least one micro- or nano-sized inorganic particle of silicon oxide; The bioceramic composition of claim 4 comprising:
10. 10. The bioceramic composition of claim 9, wherein the silicon oxide is selected from the group consisting of silicon oxide, fumed silica, hydrophilic pyrogenic silica, and combinations thereof.
11. (a) the powder phase of the composition comprises: 20-90% by weight of at least one sorosilicate; from about 1 to about 20 weight percent of at least one curing agent; about 10 to about 50 weight percent of at least one radiopaque agent; Including, (b) the aqueous liquid carrier of the composition is about 50 to about 98 weight percent water; from about 2 to about 30 weight percent of at least one accelerator; from about 0.5 to about 10 weight percent of at least one plasticizer; The bioceramic composition of claim 8 comprising:
12. (a) the powder phase of the composition comprises: 40-70% by weight of at least one sorosilicate; from about 2 to about 10 weight percent of at least one curing agent; about 20 to about 40 weight percent of at least one radiopaque agent; Including, (b) the aqueous liquid carrier of the composition is about 70 to about 85 weight percent water; from about 5 to about 20 weight percent of at least one accelerator; from about 1 to about 5 weight percent of at least one plasticizer; The bioceramic composition of claim 8 comprising:
13. The non-aqueous paste form is 10-60% by weight of at least one sorosilicate; From about 20 to about 60% by weight of at least one non-aqueous liquid carrier; about 30 to about 70 weight percent of at least one radio-opacifying agent; about 1 to about 20 weight percent of a curing agent; about 0.5 to about 10 weight percent of a rheology control agent; The bioceramic composition of claim 9 comprising:
14. The non-aqueous paste form is 20-40 wt. % of at least one sorosilicate; from about 20 to about 40% by weight of at least one non-aqueous liquid carrier; about 20 to about 40 weight percent of at least one radio-opacifying agent; about 2 to about 10 weight percent of a curing agent; about 1 to about 5 weight percent of a rheology control agent; The bioceramic composition of claim 9 comprising:
15. 13. A method for inducing tissue regeneration (excluding in humans) comprising placing the bioceramic composition of claim 1 into tissue to be repaired.
Citation Information
Patent Citations
Method for manufacturing in situs of lightweight fly ash-based aggregates
JP2014501221A
Biocompatible materials and their use
JP2014516714A
Curing improvement of sclerosing bone substitutes
JP2016513064A
biphasic ceramic bone substitute
JP2018514248A
Composition of labeled and non-labeled monoclonal antibodies
WO2008119493A1
